Ruzicka T, Assmann T, Homey B
Department of Dermatology, University of Düsseldorf, Germany.
Arch Dermatol. 1999 May;135(5):574-80. doi: 10.1001/archderm.135.5.574.
Tacrolimus has been shown to be a powerful suppressor of the immune system. It was introduced into clinical use to prevent allograft rejection and is now routinely used in kidney, liver, and heart transplantation. Recently, 2 double-blind multicenter studies demonstrated the therapeutic efficacy of topical and systemic tacrolimus in the inflammatory skin diseases atopic dermatitis and psoriasis.
MEDLINE was searched for relevant publications and combined with our own clinical, in vitro, and in vivo studies.
All studies dealing with tacrolimus and dermatology were reviewed.
Publications with clinically relevant data were included in this review.
Topical tacrolimus is a safe and effective therapeutic agent that may open a new era in the treatment of inflammatory skin diseases, particularly for patients with atopic dermatitis. Before its full potential in dermatology can be assessed, more clinical experience in treating children and comparison with the criterion standard of anti-inflammatory therapy, glucocorticosteroids, are needed.
他克莫司已被证明是一种强大的免疫系统抑制剂。它被引入临床用于预防同种异体移植排斥反应，目前常用于肾脏、肝脏和心脏移植。最近，两项双盲多中心研究证明了局部和全身应用他克莫司治疗炎症性皮肤病特应性皮炎和银屑病的疗效。
检索MEDLINE以获取相关出版物，并结合我们自己的临床、体外和体内研究。
对所有涉及他克莫司和皮肤病学的研究进行了综述。
本综述纳入了具有临床相关数据的出版物。
局部应用他克莫司是一种安全有效的治疗药物，可能会开创炎症性皮肤病治疗的新时代，特别是对于特应性皮炎患者。在评估其在皮肤病学中的全部潜力之前，需要更多治疗儿童的临床经验，并与抗炎治疗的标准药物糖皮质激素进行比较。
